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Abstract
Background: Relapses of epithelial ovarian carcinoma (EOC) have a poor prognosis and are almost always fatal.
The aim of this study was to evaluate the clinical outcome and toxicity of intraoperative electron beam radiation
therapy (IOERT) in advanced and recurrent EOC.
Methods: Forty-five women with EOC were treated with IOERT. Twenty-five patients had primary disease (PD)
without distant metastasis at IOERT, and 20 patients had an isolated local recurrence (ILR) after surgery. All 45
patients in this series underwent optimal cytoreductive (≤ 1 cm) surgery. The whole pelvic (WP) radiotherapy was
intraoperatively delivered using 12 Mev electron beam; 43 patients received 18-20 Gy and two patients received 10
Gy. Thirty-three patients received postoperateive intraperitoneal (IP) chemotherapy, while seven patients received
intravenous (IV) chemotherapy. Five patients refused concurrent chemotherapy. Overall survival (OS) rates were
analyzed using the Kaplan-Meier method.
Results: Tumor recurrence and metastasis were observed in 16 patients (35.6%). Of those, 14 patients (31.1%)
relapsed and two patients (4.4%) had distant metastasis alone. Eight of 25 (32%) local failures were observed in the
PD group, as compared to 6/20 (30%) in the ILR group (P = 0.885). Actuarial local control at five year follow-up was
31/45 (68.9%). Seventeen of the total 45 (37.8%) patients died. Nine of 25 (36%) in the PD group died, as
compared to 8 of 20 (40%) in the ILR group. The 5-year OS and disease-free survival (DFS) rates were 28/45 (62.2%)
and 25/45 (55.6%), respectively. In the PD group, the 5-year OS and DFS rates were 16/25 (64%) and 14/25 (56%) (P
> 0.05, vs. the ILR group at 12/20 and 11/20, respectively). The OS and DFS in the IOERT plus IP group were 25/33
(75.8%) and 23/33 (69.7%), respectively, which were superior to the rates achieved with IOERT plus IV
chemotherapy (P < 0.05, 2/7 and 1/7, respectively). The major complication of IOERT was neuropathy. Five (11.1%)
patients developed peripheral neurotoxicity.
Conclusions: IOERT may be feasible and effective as a boosting technique for advanced and recurrent ovarian
cancer. IOERT plus IP chemotherapy may achieve high locoregional disease control and survival benefit with a low
risk of toxicity. Peripheral nerves in the IOERT field are dose-limiting structures requiring nerve protection policies
or a dose compromise to ensure against severe neurological damage.
Background
Relapses of epithelial ovarian carcinoma (EOC) have a
poor prognosis and are almost always fatal. The prog-
nosis remains poor due to a high rate of recurrence.
About 50-75% of women with ovarian cancer will
develop persistent or recurrent disease [1]. The pelvis or
abdomen is the initial recurrence site, accounting for
approximately 85% of ovarian cancers [2]. Overall survi-
val (OS) after recurrence depends on patient’sp e r f o r -
mance status, and histological type and size of the
relapse tumor [3-5]. Pelvis, peritoneum, liver, lung,
lymph nodes, and central nervous system are the most
frequent sites of relapse [6-8]. Platinum/paclitaxel-based
chemotherapy is the current standard of treatment after
surgical staging and resection of abdominal and pelvic
cancers. Despite the advances in chemotherapy,
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patients develop abdominal or pelvic recurrence that is
resistant to further chemotherapy. Radiotherapy has
been shown to produce a response in chemo-resistant
ovarian cancers, and may offer the possibility of
improved tumor control.
Intraoperative electron beam radiation therapy
(IOERT) is an innovative boosting technique used to
deliver single high-doses of radiation (range of 10-20
Gy). One of the key advantages of this technique is the
ability to irradiate selected anatomic areas that had been
identified during the surgical procedure as high risk
and/or residual disease sites, while avoiding surrounding
dose-limiting structures. Thus, non-cancerous intra-
abdominal organs can be protected from receiving full
doses of irradiation, ultimately decreasing the incidence
of severe enteritis and increasing the local control rates
[9]. Studies of IOERT in multiple anatomical sites have
produced valuable results in terms of locoregional con-
trol and toxicity [8,10].
It is generally anticipated that IOERT may represent
an innovative treatment to improve the local control of
EOC. Numerous non-randomized series trials over the
past several years have demonstrated that IOERT was
able to reduce the local recurrence rate of various can-
cers and had a positive impact on survival [11-13]. How-
ever, there is a paucity of literature discussing the utility
of IOERT as a modality for treatment of ovarian carci-
noma. The aim of this study was to retrospectively
review all cases of EOC that were treated with IOERT
at our center over the past ten years in order to evaluate
the clinical efficacy of IOERT. We specifically addressed
patient outcome and IOERT toxicity, so as to suggest
the best parameters for its use as a therapeutic strategy.
Methods
Patients
This study was a non-randomized trial and included ret-
rospective analysis of 45 women with EOC who were
treated with IOERT at the 1st Affiliated Hospital of the
Medical College of Xi’an Jiaotong University between
January 2000 and January 2010. Twenty-five patients
had primary disease (PD) without distant metastasis at
IOERT, and 20 patients had an isolated local recurrence
(ILR) after surgery. Patients with prior postoperative
adjuvant treatments, such as chemotherapy, were
included in the analysis. The present study was
approved by the ethics committee of the 1st Affiliated
Hospital of Medical College of Xi’an Jiaotong University.
All patients had provided written informed consent for
the IOERT procedure. Inclusion criteria were a history
of EOC, diagnosed by clinical examination and CT scan,
with histological evidence. The following features were
studied: initial stage by standards of the International
Federation of Gynecology and Obstetrics (FIGO), initial
performance status, CA125 level, response to IOERT
and chemotherapy, time and sites of relapse, OS and
disease-free survival (DFS). Disease progression was
defined as: new lesions, consistent with new sites of dis-
ease, detected by imaging, including CT, magnetic reso-
nance imaging (MRI), ultrasound and/or plain X-ray;
new elevation of CA-125; biopsy/histology of new
lesions and new signs upon clinical examination, or
symptoms consistent with new sites of disease (Table 1).
IOERT procedure
All 45 patients in this series underwent optimal cytore-
ductive (≤ 1 cm) surgery. The whole pelvic (WP) radio-
therapy was delivered intraoperatively using 12 Mev
electron beam (Varian 1800). Forty-three patients
received 18-20 Gy and two patients received 10 Gy. The
superior border of the field was at the bifurcation of
common iliac vessels, while the inferior border covered
2 cm inferior to the operated vaginal vault, and laterally
1 cm beyond the lateral margin of external and common
iliac vessels. The electron intraoperative applicator was
10-12 cm in diameter. The bladder, intestines, and sig-
moid colon were shifted out of the radiation field, and
the rectum was shielded with a 6 mm thick lead sheet.
The portion of the obturator nerve in the pelvic region
was partially shifted out of the radiation field, as
allowable.
Postoperative therapy
Our institution had implemented a single day outpatient
intraperitoneal (IP) chemotherapy regimen following
IOERT, based upon careful review of the most current
published data. Every three weeks 100 mg/m
2 cisplatin
was administered, for an intended six cycles. Thirty-two
IOERT patients received four to six courses of the IP
chemotherapy regimen. Seven patients received intrave-
nous (IV) chemotherapy using 80 mg/m
2 cisplatin, 50
mg/m
2 adriamycin, and 500 mg/m
2 cyclophosphamide;
the IV regimen was designed to treat patients once
every 21 days for an intended six cycles. One patient
was treated with two courses of IP chemotherapy plus
Table 1 Patient Characteristics
Total PD ILR
Cases 45 25 20
Histology type
serous adenocarcinoma 36 21 16
papillary adenocarcinoma 9 4 4
CA-125 level
≥ 35 U/ml 38 20 18
< 35 U/ml 4 3 1
unkown 3 2 1
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altogether (Table 2).
Evaluation of acute and late toxicities
Acute and late toxicities were graded by the Common
Terminology Criteria for Adverse Events (CTCAE v3.0)
and the Radiation Therapy Oncology Group/European
Organization for Research and Treatment of Cancer
(RTOG/EORTC) criteria, respectively. Complications
that occurred within 90 days of the start of primary
treatment were considered to be acute complications,
and those that occurred more than 90 days after the
start of treatment were considered to be late
complications.
Statistical analysis
Overall survival and disease-free survival curves were
calculated according to the Kaplan-Meier method. A P-




The median age of the 45 patients at the time of EOC
diagnosis was 52.9 years (range: 42-62 years). Twenty-
five patients were treated for PD and 20 patients for
ILR. All patients of the primary tumor group were posi-
tive for peritoneal cytology and were diagnosed as FIGO
stage III. CA-125 serum levels were elevated in 38
patients, normal in four patients, and non-assessed in
three patients. Histology of the adenocarcinoma was ser-
ous in 80% (36 patients) and papillary in the remaining
20% (9 patients) (Table 1). Abnormal CA-125 (defined
as a level > 35 U/mL) was observed in 84.4% of patients
at pre-treatment, 64.4% after IOERT and one cycle of IP
chemotherapy, 15.6% after three cycles of IP chemother-
apy, and 6.7% at the end of chemotherapy.
During the follow-up interval, 17 (37.8%) patients
died. Thirteen (28.9%) died of tumor-related disease,
and four died of causes other than cancer. Tumor recur-
rence and metastasis were observed in 16 patients
(35.6%). In the entire group, 14 patients (31.1%) relapsed
and two patients (4.4%) had distant metastasis alone; of
those two, one had abdominal relapse and lung metasta-
sis, and the other had lung, liver, and spleen metastases.
Among them, isolated local recurrence was detected in
11 patients (24.4%), and combined local failure and dis-
tant metastasis was detected in three patients (6.7%).
Eight of the 25 (32%) local failures were observed in the
PD group, compared to those in the ILR group (6/20,
30%; P = 0.885). Actuarial local control at five years fol-
low-up was 31/45 (68.9%). The rates of distant metasta-
sis were similar among the two groups (3/25 in PD and
2/20 in ILR; P = 0.832). The mean times to recurrence
in the PD and ILR groups were eight months (range: 7-
11 months) and 10 months (range: 3-34 months),
respectively. Ten of the 14 local failures were deter-
mined to be locoregional failure in the abdomen tissue,
outside of the IOERT targeted region.
OS and DFS
The mean follow-up time was 78 months (range: 11-123
months). During that time, 17 of 45 (37.8%) patients
died of disease. Nine of the 25 patients (36%) in the PD
group died, as compared to eight of the 20 patients
(40%) in the ILR group. The 5-year overall survival and
disease-free survival rates were 28/45 (62.2%) and 25/45
(55.6%), respectively. In the PD group, the 5-year OS
and DFS rates were 16/25 and 14/25 (P >0 . 0 5vs.t h e
ILR group at 12/20 and 11/20, respectively) (Figure 1a
and 1b). The OS and DFS in the IOERT plus IP group
were 25/33 and 23/33, which were superior to those in
the IOERT plus IV group (2/7 and 1/7, respectively; P <
0.05) (Figure 1c and 1d).
Toxicities
Generally, IOERT was well tolerated. The toxicities
noted included only those potentially related to local
effects from local treatments. Toxicity related to che-
motherapy was not noted. No radiation-induced nausea
or vomiting was observed. No delayed wound healing
occurred in any of the patients. No patients with
abdominal relapse suffered small bowel obstruction dur-
ing the entire follow-up period.
The major complication was neuropathy. Five
(11.1%) patients developed neurotoxicity; grade1 and 2
peripheral neuropathy was cited most frequently. The
median time to the onset of neurotoxicity was 14
months (range: 8-22 months). In three cases, the nerve
had been included in the IOERT field, indicating the
chance of developing neuropathy was 16.7% if the per-
ipheral nerve had been included in the IOERT field. In
two out of 27 patients (7.4%), the nerve had not been
irradiated. In addition, one patient suffered abdominal
pain (2.2%) and two patients (4.4%) developed
hydronephrosis.
Other toxicities, such as urinary tract infection (2.2%),
intestinal injury (4.4%) and crura edema (2.2%) were
reported as related to surgery. All cases were sufficiently
managed by conservative treatment.
Table 2 Therapy Types
Therapy Types Total PD ILR
IOERT+IP(4-6 courses) 32 17 15
IOERT+IP(2 courses) 1 0 1
IOERT+IV 7 5 2
IOERT 5 3 2
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Ovarian carcinoma is the second most common gyneco-
logic cancer and the leading cause of death from gyne-
cologic malignancy. Epithelial ovarian cancer represents
the primary cause of death from gynecological cancer in
Western countries, with approximately 26000 new cases
diagnosed in the United States each year [14-17]. More
than two-thirds of patients with epithelial ovarian cancer
are diagnosed in an advanced stage of disease at presen-
tation because of the absence of specific signs and
symptoms. The 5-year overall survival ranges from 89%
for stage IA to 13% for stage IV disease, according to
the annual report from FIGO [18]. About 40-85% of
patients who have stage II to IV disease will relapse
after primary therapy and develop abdominal or pelvic
recurrence; these tumors are also characterized by a low
response rate to further chemotherapy and subsequent
poor prognosis (5-year survival rate < 25%) [19,20].
Invasion of the ovarian capsule and dissemination in the
peritoneal cavity is the main route by which ovarian car-
cinoma spreads [21], accounting for about 82% of cases;
in contrast, only 12% of ovarian metastatic events
involve the retroperitoneal lymph nodes [19].
Platinum/paclitaxel-based chemotherapy is the current
standard of treatment after surgical staging and resec-
tion of abdominal and pelvic cancers. Despite the signif-
icant advances in treatment, however, the prognosis
remains poor since the standard therapy does not lead
to a sufficient reduction of tumor cells and fails to cure.
Abdominal radiotherapy offers the possibility of
Figure 1 Survival analysis in advanced and recurrent epithelial ovarian carcinoma after IOERT. a Overall-survival curve stratified for PD
versus ILR (P > 0.05). b Disease-free survival survival curve stratified for PD versus ILR (P > 0.05). c Overall-survival curve stratified for IOERT+IP
versus IOERT+IV (P < 0.05). d Disease-free survival curve stratified for IOERT+IP versus decreased IOERT+IV (P < 0.05).
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radiotherapy for improving disease control in the abdo-
men and pelvis may increase the disease-free interval
and survival [22]. To date, however, there has been no
proven benefit and there is significant toxicity associated
with this treatment. Thus, an alternative effective ther-
apy is urgently needed.
IOERT improves the therapeutic ratio by decreasing
the toxicity in dose-limiting normal tissues that can be
displaced or protected. It can be administered as an
upfront radiation boost, simultaneously with surgical
resection, which might allow total electron beam radia-
tion therapy (EBRT) dose to be decreased without jeo-
pardizing local control or survival. Another possible
advantage of IOERT is that it might indirectly improve
the quality of therapy by decreasing the overall treat-
ment time as a secondary endpoint [23]. IOERT clinical
trials have also been mainly conducted on patients with
locally advanced malignancies in the abdomen and pel-
vis [8,24]. In this study, we observed that it was espe-
cially effective in patients who had an adequate
resection of their localized extraperitoneal recurrence
and a significant survival benefit whether the patients
had primary disease or not. The 5-year overall survival
rates were 64% in the PD group and 60% in the ILR
group. Non-IORT approaches have been reported in the
literature as producing OS rates of 20.6% for primary
ovarian patients (stage III) and < 25% for recurrent
cases [19,20,25].
Among the 14 patients with local failures in our study,
a significant proportion (10/14) of the relapse sites were
found outside of the IOERT targeted region. In addition,
with the low toxicity associated with IOERT, the quality
of life was considered an important endpoint in these
patients, which is particularly dependent on strategies
providing high local control rates and organ preserva-
tion, such as bladder, intestines, sigmoid colon, and the
pelvic portion of the obturator nerve). Moreover, in this
series we have shown that disease limited to the local
and regional areas can be successfully treated with sig-
nificant overall survival and disease-free survival. Even
though ovarian cancer is known to have high incidence
of widespread metastases, this is not always the case.
Our regimen also exhibited a favorable survival time,
even in cases of abnormal CA-125 levels at pre-treat-
ment and obvious decline in CA-125 serum level follow-
ing tumor resection, IOERT, and IP chemotherapy. A
study by Krivak et al. found that patients with an abnor-
mal CA-125 (> 35 U/mL) prior to treatment were 2.45
times more likely to experience disease progression and
2.78 times more likely to die of disease, as compared to
patients with CA-125 < 35 U/mL [26].
Although the absolute number of toxicities was lower
in the present study, the incidence rate of neurotoxicity
seems high. Neuropathy is a dose-limiting toxicity in
IOERT and other anatomic sites treated with this mod-
ality. Animal studies have shown that the tolerance of
nerve structures to IOERT may be lower than 15 Gy
[15]. In the present series, 11% of the patients developed
symptoms associated with peripheral neuropathy. In
four of these patients, substantial improvement was
observed over time, with successful recovery noted at
prolonged follow-up. Peripheral nerves in the IOERT
field are dose-limiting structures requiring a dose com-
promise or the activation of the nerve protection poli-
cies in the IOERT component to avoid severe
neurological damage.
In addition, the findings from this study suggested
that subsequent IP chemotherapy may have improved
the local control rates. This is consistent with a report
by Chin et al. [27]. Combined treatment modalities
increase the effect of radiation significantly. IP che-
motherapy was first proposed in the 1970s as a way to
maximize drug delivery to the tumor while avoiding sys-
temic toxicities associated with IV administration of the
same agents [28-30]. The results of the Gynecologic
Oncology Group (GOG-172) phase III trial demon-
strated that bidirectional chemotherapy using IV pacli-
taxel plus IP cisplatin and paclitaxel significantly
improved survival in patients with optimally debulked
stage III disease [1]. Based on these results, the National
Cancer Institute and GOG have issued a clinical
announcement recommending that patients with stage
III ovarian cancer should be considered for IP che-
motherapy after undergoing optimal surgical cytoreduc-
tion [31]. Owing to the unique properties of the
peritoneum, IP chemotherapy affords the opportunity to
use higher concentrations of drugs for prolonged peri-
ods of time, directly bathing resected tumor beds, lymph
node basins, and residual tumor nodules in the thera-
peutic agent. Unfortunately, IP chemotherapy is still
limited by the fact that it cannot penetrate into large
tumor nodules, essentially 3 mm or greater; IOERT may
be able to do this, however [32]. Our retrospective study
suggests that IOERT plus IP chemotherapy may be a
useful treatment for selected patients with EOC. There-
fore, with the encouraging results of this report, IOERT
plus IP chemotherapy should be further studied for its
utility in chemoresistant patients with recurrent ovarian
cancer.
Although IOERT has been recommended for recur-
rent cervical cancer by the National Cancer Institute
[33], to our knowledge, the present report represents
the first systematic review of the activity of IOERT plus
IP chemotherapy against EOC. The limitations of this
report are those associated with any retrospective study,
including potential referral bias, other types of selection
bias, and a variety of treatments, doses, and schedules.
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investigated in detail, and this research did not reach
statistical significance because of the small numbers in
this series; nonetheless, we did observe a marked advan-
tage in overall survival and disease-free survival. We
have also demonstrated that the involved field of radia-
tion therapy was relatively unaffected in this heavily pre-
treated population.
The findings of this study confirm our clinical impres-
sions and provide important information with which to
move forward in developing better therapies for
advanced and recurrent carcinoma of the ovary. Addi-
tionally, the current systemic therapy options are all
associated with toxicities that are potentially detrimental
to a patient’s overall quality of life or well-being. The
IOERT treatment provided good prognosis of EOC, and
in some cases with postoperative IP chemotherapy. A
prospective randomized control trial comparing IOERT
with various chemotherapies, established or candidates
for EOC, should be considered. Our findings also sug-
gest the need for larger studies to determine the role of
IOERT in local and regional control and to evaluate its
impact on distant metastasis and overall survival in
advanced and recurrent ovarian cancers.
Conclusions
IOERT may be feasible and effective as a boosting tech-
nique to treat advanced and recurrent ovarian cancers.
IOERT plus IP chemotherapy may achieve high locore-
gional disease control and survival benefit with a low
risk of toxicity. However, careful attention should be
paid to peripheral nerves as specific IOERT dose-limit-
ing structures.
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